MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech's Big Market Movers (ReproCELL)

ReproCELL    

ReproCELL

 

ReproCELL is a stem cell company emerging as a venture out of the University of Tokyo and Kyoto University. The company commercialized the first human products, iPS cell products, in 2009. These cells are are "adult cells that have been genetically reprogrammed to an embryonic stem cell–like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells," according to the National Institutes of Health.

Last year, the Japanese company's share price plummetted 55%, to 773 Japanese yen ($6.48) from 1,725 Japanese yen ($16.38) at the end of 2013. As a result, the company lost $439 billion from its market cap.

             
           

 

 

TAGS: News
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish